Medinova Diagnostic Services Limited
Medinova Diagnostic Services Limited Fundamental Analysis
Medinova Diagnostic Services Limited (MEDINOV.BO) shows moderate financial fundamentals with a PE ratio of 19.99, profit margin of 21.57%, and ROE of -1.80%. The company generates $0.1B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 428.3/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.
Fundamental Health Score
We analyze MEDINOV.BO's fundamental strength across five key dimensions:
Efficiency Score
ExcellentMEDINOV.BO demonstrates superior asset utilization.
Valuation Score
ModerateMEDINOV.BO shows balanced valuation metrics.
Growth Score
ModerateMEDINOV.BO shows steady but slowing expansion.
Financial Health Score
ExcellentMEDINOV.BO maintains a strong and stable balance sheet.
Profitability Score
WeakMEDINOV.BO struggles to sustain strong margins.
Key Financial Metrics
Is MEDINOV.BO Expensive or Cheap?
P/E Ratio
MEDINOV.BO trades at 19.99 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, MEDINOV.BO's PEG of 21.28 indicates potential overvaluation.
Price to Book
The market values Medinova Diagnostic Services Limited at -516.39 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 11.32 times EBITDA. This signals the market has high growth expectations.
How Well Does MEDINOV.BO Make Money?
Net Profit Margin
For every $100 in sales, Medinova Diagnostic Services Limited keeps $21.57 as profit after all expenses.
Operating Margin
Core operations generate 33.39 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-1.80 in profit for every $100 of shareholder equity.
ROA
Medinova Diagnostic Services Limited generates $28.25 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Medinova Diagnostic Services Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Medinova Diagnostic Services Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
MEDINOV.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
19.99
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
21.28
vs 25 benchmark
P/B Ratio
Price to book value ratio
-516.39
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.35
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-48.02
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.48
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-1.80
vs 25 benchmark
ROA
Return on assets percentage
0.28
vs 25 benchmark
ROCE
Return on capital employed
0.80
vs 25 benchmark
How MEDINOV.BO Stacks Against Its Sector Peers
| Metric | MEDINOV.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 19.99 | 29.45 | Better (Cheaper) |
| ROE | -179.97% | 779.00% | Weak |
| Net Margin | 21.57% | -24936.00% (disorted) | Strong |
| Debt/Equity | -48.02 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 1.48 | 4.65 | Neutral |
| ROA | 28.25% | -19344.00% (disorted) | Strong |
MEDINOV.BO outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Medinova Diagnostic Services Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation